Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) is a preclinical-stage pharmaceutical company focused on non-opioid, non-addictive pain management and central nervous system (CNS) disorders, using novel drug delivery technologies. The Virpax news feed on Stock Titan highlights company announcements that describe progress across its prescription and nonprescription product candidates and capital markets activity.
News items commonly cover Virpax’s pipeline developments, such as preclinical dose range finding studies and animal model data for Probudur™, its long-acting liposomal bupivacaine formulation for post-operative pain. Releases also discuss updates on Envelta™ (NES100), an intranasal molecular envelope enkephalin formulation for acute and chronic pain, and NobrXiol™, an intranasal cannabidiol (CBD) candidate for rare pediatric epilepsy that uses Molecular Envelope Technology (MET) to target delivery to the brain.
Investors can follow announcements about Virpax’s collaborations and CRADAs with organizations such as the National Institutes of Health, the Department of Defense, and the U.S. Army Institute of Surgical Research, which has evaluated Probudur in combat care-related pain models. The news stream also includes updates on MET-related studies conducted by partners like Nanomerics, including human safety data for MET-based formulations.
In addition, Virpax issues news regarding financing transactions, including public offerings of common stock and pre-funded warrants, and corporate actions such as reverse stock splits intended to support continued listing on the Nasdaq Capital Market. The company also reports on exploratory work using MET or similar technology for intranasal mRNA COVID vaccine delivery and on efforts to seek partners for nonprescription candidates such as AnQlar and Epoladerm.
By monitoring this page, readers can review Virpax’s official press releases on its research progress, regulatory interactions, collaborations, and capital markets events in one place.
Virpax Pharmaceuticals (NASDAQ: VRPX) has partnered with Charles River Laboratories to commence preclinical studies for Epoladerm™, a patented topical spray for acute musculoskeletal pain. This agreement includes seven animal studies to ascertain the necessary dosages and toxicity for FDA compliance. Following these studies, Virpax plans to submit its Investigational New Drug Application in H1 2021. Epoladerm™ uses a meter-dosed film to deliver Diclofenac Epolamine and is expected to accelerate the drug approval process.
Virpax Pharmaceuticals (NASDAQ:VRPX) announced the issuance of US Patent No. 10842745 for a liposomal composition containing bupivacaine, set to expire in 2029. This patent, exclusively licensed to Virpax from LipoCure Rx, includes 18 claims related to methods for providing analgesia. CEO Anthony Mack expressed satisfaction with the growing patent portfolio for Probudur™, a long-acting anesthetic for postoperative pain management. The company is focused on developing non-addictive pain management products using proprietary technologies.
Nanomerics Ltd announced receiving its first milestone payments from Virpax Pharmaceuticals (NASDAQ:VRPX). These payments are linked to the licensing of Envelta™ for non-cancer pain treatment and MMS019, an antiviral nasal spray. Virpax is responsible for clinical development under agreements with the U.S. National Center for Advancing Translational Sciences. This collaboration supports the development of innovative treatments amid the opioid crisis and viral infections, potentially enhancing both companies’ market positions.
Virpax Pharmaceuticals (NASDAQ:VRPX) announced the initiation of IND enabling studies for its intranasal enkephalin drug candidate, Envelta™, in collaboration with the National Center for Advancing Translational Sciences (NCATS). This partnership aims to expedite the company's path towards FDA clearance for its first-in-human clinical trials. Envelta™ utilizes nanotechnology for drug delivery directly to the brain, potentially offering a non-addictive pain management alternative. The CEO emphasized that these studies mark significant progress in clinical development strategy.
Virpax Pharmaceuticals has successfully closed its IPO, offering 1,800,000 shares at $10.00 each, raising $18.0 million before expenses. The underwriters received a 30-day option to purchase an additional 270,000 shares for over-allotments. The net proceeds will primarily fund research for its product pipeline, including Epoladerm™ and Probudur™, among others. The registration statement was filed with the SEC and became effective on February 16, 2021.
Virpax Pharmaceuticals has priced its initial public offering of 1,800,000 shares of common stock at $10.00 per share, aiming for gross proceeds of $18 million. An additional 270,000 shares may be purchased by underwriters for overallotments. Trading on the Nasdaq under the symbol VRPX is set to begin on February 17, 2021, with the offering closing expected by February 19, 2021. The funds will primarily support R&D for products like Epoladerm™, Probudur™, and others. ThinkEquity is the sole manager for this offering.